Aix-en-Provence, 10 September 2025 (6 p.m.) HIGHCO: DECLINE IN H1 2025 FINANCIAL PERFORMANCE AS FORECAST; ACQUISITION OF SOGEC AND BUDGETBOX IN PROGRESS; FURTHER UPWARD REVISION IN 2025 GUIDANCE Business decline in line with expectations in H1 2025H1 2025 gross profit of €30.96 m, down 8.2% LFL1. Half-year growth in the Activation division continues to be driven by France (up 3.1% LFL), decline in Mobile businesses (down 7.8% LFL) and sharp decrease, as expected, in Consulting & In-store media selling due to Casino (down 32.1% LFL). Businesses decline in France (down 7.9% LFL) and in International business (down 10.1% LFL).Drop in results and profitability as anticipatedAdjusted headline PBIT2 of €5.05 m, down 33.4%. Adjusted operating margin2 of 16.3%, down 620 basis points. Adjusted attributable net income4 of €3.86 m, down...

PRESS INFORMATIONHeading: 1st half 2025 results        Nanterre, September 10, 2025 (after trading) 6.3% net profit in 1st half 2025(in millions of euros) H1 2024 2024 H1 2025 *Revenues 402.4 810.4 424.3Business operating profit ** 40.5 (10.1%) 84.1 (10.4%) 37.4 (8.8%)Operating profit 37.1 (9.2%) 77.9 (9.6%) 33.1 (7.8%)Net financial profit 4.7 10.2 4.8Income tax (12.6) (24.9) (11.1)Net profit after tax 29.2 (7.3%) 63.2 (7.8%) 26.8 (6.3%)of which, group share 24.5 52.5 22.7Net cash excluding financial debt *** 256.9 319.5 282.2Staff at end of period (ppl) 7,001 7,087 7,264* Financial statements as of June 30, 2025, approved by the Board of Directors on September 10.** Before cost of bonus shares.*** Excluding IFRS16 lease liabilities. Achievements As previously announced, the Group posted growth of 5.4%...

$3.7 billion in minimum contracted revenue Dynamic renewal program – 21 new buildings under construction, incl. 3 new South Korean VLCC orders TEN’s fleet carrying capacity reaches 11 dwt $0.60 common stock dividend paid in July 2025 Tanker Market Fundamentals Remain Strong ATHENS, Greece, Sept. 10, 2025 (GLOBE NEWSWIRE) — TEN, Ltd (TEN) (NYSE: TEN) (the “Company”) today reported results (unaudited) for the six months and the second quarter ended June 30, 2025. FIRST HALF 2025 SUMMARY RESULTSTEN’s fleet generated $390.4 million in gross revenues resulting to approx. $111.0 million in operating income, inclusive of $3.6 million of capital gains. Adjusted EBITDA for the first half of 2025 was $193.2 million. The net income for the first half of 2025 was $64.5 million or $1.70 per share. Fleet utilization increased to 96.9% in the...

ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl which has been granted a Type C meeting on September 18th. Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of $1,289,884, up 50.87% YOY. Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse...

Operating Profit of $23 million Operating Margin of 10.6% Orders +35% YoY Operating Cash Flow of $26 million, +34% YoY; Ending Cash Balance of $137 million Business and Digital Transformation on Track; Reiterating Three Year Forward Objectives of 7-10% Sales Growth, 10-12% operating margin, 17-20% ROIC BROOKINGS, S.D., Sept. 10, 2025 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ-DAKT) (the “Company”, “Daktronics”, “we”, or “us”), a recognized industry leader in the design and manufacturing of best-in-class dynamic video communication displays and control systems for customers worldwide, today reported results for its fiscal 2026 first quarter which ended August 2, 2025. Fiscal 2026 is a 53-week year and fiscal 2025 was a 52-week year; therefore, the three months ended August 2, 2025 contains operating results for 14 weeks while...

BV100: successful end of Phase 2 meeting with US FDA following Positive Phase 2 read-out in Ventilator-Associated Bacterial Pneumonia (VABP); Phase 3 on track to initiate in 2025; Formulation patent granted in China, extending BV100 IP protection to over 25 countries, including the US, Europe and the UK Alpibectir: First patient dosed in a Phase 2 combination trial in pulmonary Tuberculosis by partner GSK – first top line data expected in Q2 2026; EMA Orphan Designation received for Alpibectir and ethionamide combination for the treatment of tuberculosis BV500: Entered into Global Research Collaboration and exclusive license agreement with Shionogi to jointly develop a broad-spectrum non-tuberculous mycobacteria (NTM) clinical candidate Improved FY 2025 Financial Guidance with CHF 29m in expected Operating Loss and CHF 78m in Cash &...

Momentum Building with New Contracts, Record Revenue, and Growing Interest Across Multiple Markets GOLETA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) — Aeluma, Inc. (NASDAQ: ALMU) (“Aeluma” or the “Company”), a transformative semiconductor company specializing in high-performance and scalable technologies, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025. Management Commentary “Throughout fiscal year 2025, we continued to build momentum with increased manufacturing readiness, commercialization traction, and elevated market visibility following our Nasdaq uplist,” said Jonathan Klamkin, Ph.D., Founder and CEO of Aeluma. “Our transformative semiconductor technology uniquely positions us to address critical needs in several fast-growing market verticals, including AI infrastructure, defense...

HAVERTOWN, Pa., Sept. 09, 2025 (GLOBE NEWSWIRE) — AMREP Corporation (NYSE:AXR) today reported net income of $4,692,000, or $0.87 per diluted share, for its 2026 fiscal first quarter ended July 31, 2025 compared to net income of $4,064,000, or $0.76 per diluted share, for the same period of the prior year. Revenues were $17,851,000 for the first quarter of 2026 and $19,091,000 for the first quarter of 2025. More information about the Company’s financial performance may be found in AMREP Corporation’s financial statements on Form 10-Q which have today been filed with the Securities and Exchange Commission and will be available on AMREP’s website (www.amrepcorp.com/sec-filings/). As a result of many factors, including the nature and timing of specific transactions and the type and location of land or homes being sold, revenues, average...

Increased gross margin approximately 90 basis points Reduced inventory for the ninth consecutive quarter DODGEVILLE, Wis., Sept. 09, 2025 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the second quarter ended August 1, 2025. Andrew McLean, Chief Executive Officer, stated: “As we reflect on the past several months – including the second and into the third quarter – we’re seeing clear, encouraging momentum across our businesses. In our consumer business, tangible improvements in key product categories, channels, and customer engagement reinforce our confidence that our strategy of providing solutions for every customer journey is working. Further, our weatherproofed assortment and shift toward an asset-light, low-intensity model are enabling us to rapidly introduce new products that resonate...

SANTA PAULA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global leader in sourcing, packing and distribution of fresh avocados, tomatoes, papayas and processing of guacamole and other avocado products, today reported its financial results for the third fiscal quarter and nine-month period ended July 31, 2025. Third Quarter Financial OverviewTotal net sales were $178.8 million, a decrease of less than one percent from the prior year.Fresh segment sales were $155.9 million, a 5% decrease from the prior year. Prepared segment sales were $22.9 million, a 40% increase from the prior year.Gross profit was $18.2 million, a 9% decrease from the prior year quarter. This quarter included approximately $4.2 million of discrete costs associated with a temporary Food and Drug Administration (“FDA”)...